Mark Vignola - Terns Pharmaceuticals CFO Treasurer
| TERN Stock | USD 5.79 0.08 1.40% |
Insider
Mark Vignola is CFO Treasurer of Terns Pharmaceuticals
| Age | 46 |
| Address | 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404 |
| Phone | 650 525 5535 |
| Web | https://www.ternspharma.com |
Mark Vignola Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Vignola against Terns Pharmaceuticals stock is an integral part of due diligence when investing in Terns Pharmaceuticals. Mark Vignola insider activity provides valuable insight into whether Terns Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Terns Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Terns Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Vignola over three months ago Acquisition by Mark Vignola of 65000 shares of Terns Pharmaceuticals at 5.36 subject to Rule 16b-3 | ||
Mark Vignola over three months ago Acquisition by Mark Vignola of 4791 shares of Terns Pharmaceuticals at 4.44 subject to Rule 16b-3 | ||
Mark Vignola over six months ago Purchase by Mark Vignola of 743 shares of Terns Pharmaceuticals |
Terns Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1923) % which means that it has lost $0.1923 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2828) %, meaning that it created substantial loss on money invested by shareholders. Terns Pharmaceuticals' management efficiency ratios could be used to measure how well Terns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Tharaknath Rao | Assembly Biosciences | N/A | |
| Mark Dudley | Instil Bio | N/A | |
| Linda Marbn | Capricor Therapeutics | 61 | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Chris MBA | Crinetics Pharmaceuticals | N/A | |
| Waldemar Priebe | Moleculin Biotech | N/A | |
| Julia Wilson | Achilles Therapeutics PLC | N/A | |
| Sandeep MD | Instil Bio | 55 | |
| Jeff Knight | Crinetics Pharmaceuticals | 53 | |
| AO FRACP | Assembly Biosciences | 65 | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
| Jeffery MD | Bio Path Holdings | N/A | |
| Peter MBA | Bio Path Holdings | 75 | |
| Sumita JD | Instil Bio | 50 | |
| Timothy Moore | Instil Bio | 63 | |
| Nicole White | Assembly Biosciences | N/A | |
| Anish MD | Soleno Therapeutics | 54 | |
| Michele Anderson | Assembly Biosciences | N/A | |
| Alan MacKenzie | Bio Path Holdings | N/A | |
| Anthony MBA | Capricor Therapeutics | 38 | |
Management Performance
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.19 |
Terns Pharmaceuticals Leadership Team
Elected by the shareholders, the Terns Pharmaceuticals' board of directors comprises two types of representatives: Terns Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Terns. The board's role is to monitor Terns Pharmaceuticals' management team and ensure that shareholders' interests are well served. Terns Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Terns Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pamela Danagher, Senior Assurance | ||
| Debra Sieminski, Senior Affairs | ||
| Jeffrey Jasper, Senior Research | ||
| Seokho Esq, General COO | ||
| JD Esq, Chief Officer | ||
| Senthil Sundaram, CEO Director | ||
| David Strauss, VP Controller | ||
| Kerry MD, Chief Officer | ||
| Emil MD, Chief Oncology | ||
| Weidong Zhong, CoFounder Officer | ||
| Erin MD, President Development | ||
| Amy MBA, CEO Director | ||
| Mark Vignola, CFO Treasurer | ||
| Scott Harris, Chief Officer | ||
| Diana Chung, Senior Officer | ||
| Melita Jung, Chief Officer |
Terns Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Terns Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 120.32 M | ||||
| Shares Outstanding | 84.94 M | ||||
| Shares Owned By Insiders | 0.13 % | ||||
| Shares Owned By Institutions | 97.72 % | ||||
| Number Of Shares Shorted | 4.54 M | ||||
| Price To Book | 1.35 X | ||||
| Price To Sales | 302.64 X | ||||
| Gross Profit | 1000 K |
Pair Trading with Terns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Terns Stock
Moving against Terns Stock
| 0.71 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.59 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.59 | KZR | Kezar Life Sciences | PairCorr |
| 0.49 | GILD | Gilead Sciences | PairCorr |
| 0.37 | KTTAW | Pasithea Therapeutics | PairCorr |
The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 0.035 | Return On Assets (0.19) | Return On Equity (0.28) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.